$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
[Report Updated: 24-04-2018]

Published by Global Markets Direct: 24 Apr 2018 | 209758 | In Stock
Related Topics: Diabetes , Hypercholesterolemia , Steatohepatitis , Vascular

Introduction

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018'; Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis.

It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner.

The report 'Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H1 2018' outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 10, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Type 2 Diabetes, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)

- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects

- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018 [Report Updated: 24-04-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development

    AFFiRiS AG

    Betagenon AB

    Biocad

    Bioleaders Corp

    BioLingus AG

    Dicerna Pharmaceuticals Inc

    Ensemble Therapeutics Corp

    Innovent Biologics Inc

    Kowa Co Ltd

    Noxopharm Ltd

    Pfizer Inc

    Portola Pharmaceuticals Inc

    Regeneron Pharmaceuticals Inc

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    The Medicines Company

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles

    AK-102 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    alirocumab - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AT-04A - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AT-06A - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BLSM-201 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CiVi-007 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CVILM-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DCRPCSK-9 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Fusion Proteins to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    IBI-306 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    inclisiran - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    JS-002 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    K-312 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NYX-330 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    O-304 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PF-06446846 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit PCSK9 for Hyperlipidemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SX-PCK9 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    UBP-1214 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones

    Featured News & Press Releases

    Mar 10, 2018: Praluent (alirocumab) Significantly Reduced Risk of Cardiovascular Events in High-risk Patients, and was Associated with Lower Death Rate

    Mar 10, 2018: Regeneron and Sanofi Announce Plans to Make Praluent (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need

    Mar 08, 2018: The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule

    Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

    Jan 25, 2018: Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule

    Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017

    Nov 06, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran

    Nov 02, 2017: Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

    Oct 05, 2017: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent (alirocumab)

    Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials

    Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017

    Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes

    Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

    Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran

    Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

209758 | GMDHC1430TDB

Number of Pages

98

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
23 Oct 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insight, 2018
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2018” report by...
14 Feb 2018 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
10 Oct 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action...
01 Sep 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights,...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018 [Report Updated: 24-04-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...